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The final results of my project turned out to be unusual.
Primary endpoints negative but overall outcome was excel-
lent, with a huge confidence interval and a tendency for
remarkable well-being.
The moment I heard it was Amsterdam, I made up my
mind; I was going to the European Society of Cardiology (ESC)
Congress. Not that the anticipated academic feast made me
sleepless, but the attraction and charm of Amsterdam was
magnetic. I had been there during my college days, and I still
cherish the captivating canal cruise and the magical muse-
ums. Promise of a Swarovski crystal for my wife, Toblerone
chocolates for my kids and an assurance to the hospital
medical administrator that no further leave for the next ten
years, made sure thatmy trip was on course. Few clicks on the
net confirmed my online registration, my travel agent made
sure that I got the cheapest fare and the maximum frequent
flier miles, and I was ready to go. I did a little bit of research
and my agenda was clear, Rembrandt, Van Gogh prevailed
high up on the list overriding ST segment and ejection frac-
tion. I mentally ticked Rijksmuseum and the Aalsmeer flower
market as a ‘must see’.
Surprises started a week before my travel. The conference
badge, with my name and affiliations arrived by courier; an e-
mail directed me to download an app in my android phone to
decide which session to attend and that too at what time slot.
Once I keyed in my areas of interest, it created an itinerary for
me to follow, but I was clearly not in an academic mood.
On arrival at Amsterdam’s Schiphol airport, I was greeted
by a smiling lady at the ESC booth, giving me directions as to
where to get my hotel shuttle. In 30 min, I checked into my
hotel. I thought of going to the conference venue, to avoid a
feeling of guilt, before I embark uponmy discovery of the city.
A convenient, quite and comfortable tram ride brought me to
the RAI convention center. The massive infrastructure, the
clear signage, the smooth registration process, the ambience
of the lecture halls quickly cast a magic spell on me, and I
decided to attend the Hotline session as a starter.
Dr David Wald from the Wolfson institute of preventive
medicine, Barts and London Medical School reported the
surprising result that targeting non-culprit but significant
lesions during primary angioplasty for STEMI improves out-
come (PRAMI trial). Dr Ole Frobert from Orebro University
Hospital, Sweden, presented data from 7244 patients of STEMIrandomized to either thrombus aspiration with PCI or to pri-
mary PCI alone. Surprisingly, thrombus aspiration prior to PCI
was no better than primary PCI. I didn’t know when I
instinctively took out my note book and started taking notes,
but surprise after surprise unfolded on the stage.
The newer anticoagulants had mixed luck. Edoxaban
proved better than Warfarin in venous thromboembolism
(VTE) while Dabigatran failed to break ground in mechanical
valve thromboprophylaxis. Otamixaban did not improve out-
come in NSTEMI in the TAO trial. I attributed my dizziness to
the overdose of academics and jet lag but came out to find my
cell phone vibrating to alert me that Prof Eugene Braunwald’s
lecture on ‘top ten cardiology advances’ is about to begin. The
very name of Prof Braunwald brought back emotions dating
back to my postgraduate days when we literally lived and
slept with his textbook. I ran to the hall to grab a seat just in
time.
The lecture spanned hundred years of innovations in car-
diology that made what modern cardiology is today. From
Willem Einthoven’s ECG, Werner Forssmann’s Cardiac Cath,
Mason Sones coronary angiogram, and Edlers Echo, it ferried
us through Robert Gross’s PDA closure, Desmond Julian’s
groundbreaking idea of CCUs, and Paul Dudley Whites con-
cept of preventive cardiology, ending finally with the arrival of
designer cardiovascular drugs, Zoll’s Pacemaker and Michel
Mirowskis ICD. Each of these concepts had been responsible
for substantially reducing cardiac death and disability. I was
mesmerized. By the time I came out it was evening 7, but the
Amsterdam sun was still above the horizon.
I could not resist myself from going to the RAI convention
center the next day, with a vow to get out for museum visits
after the Named lectures. The electronic display board
announced that there were 29,597 attendees that day.
Rene Laennec lecture was delivered by Silvia Priori. Even
her personal story was so invigorating that it made the audi-
ence break into an applause even before her lecture began.
After graduating from University of Milan in 1985, She had
suffered a series of fainting attacks and was referred to Peter
Schwartz to rule out long QT syndrome. While she did not
have long QT, her interest in genetic causes for chanello-
pathies crystallized during those visits. In 1996, she studied
genetics at the Telethon institute of geneticmedicine inMilan.
She mentioned how she felt when she extracted and studied
the DNA from a patient’s leukocyte for the first time. The fact
that the clue to such a bad disease hiding in a piece of DNA
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Working with Carlo Napolitano of Pavia she created a registry
of young people with arrhythmias, syncope and unexplained
cardiac arrest. Her painstaking research led to discovery of the
ryanodine receptor gene hRyR2 mutation responsible for
CPVT. Since 2008, she shares her time between Pavia and New
York University.
The Andreas Gruntzig lecture was delivered by Petr
Widimsky. He talked about catheter based thrombectomy.
“Stroke treatment is 25 years behind modern MI treatment.
PCI has become a norm for STEMI but catheter based throm-
bectomy (CBT) has not become the standard in stroke” was his
candid comment.
Under some spell of magic I walked out of the hall to enter
the Hotline sessions II. Surprises continued to jump out like
rabbits from the magician’s hat, half a dozen of them. The
new DPP4 inhibitors, saxagliptin in SAVOR TIMI 420 and
Alogliptine in EXAMINE trial showed no increase in CV event
rate, but Prof Braunwald once again pointed out that therewas
no cardio-protective signal to be happy about. In the PURE
trial, Prof Salim Yusuf pointed out that despite higher risk
factors clustering in high income countries, major CVDs and
fatalities are lower because of better medical care. His obser-
vations opened up a new area of debate and thinking.
In an adjacent hall, presenters pointed out that losartan at
a dose of 100 mg daily tended to slow down progressionaortic dilatation in Marfan syndrome, irrespective of blood
pressure lowering. In a side room, I re-learnt hands on CPR
and use of AEDs. What surprised me was that despite
numerous presentations, not one speaker went beyond
allotted time or needed to be warned of dire consequences
unless he stopped.
I did manage to have a night cruise in the canals. But I
really don’t know how those 4 days went by. On my flight
back home I thought of it. I did fail to attain my primary
endpoints of visiting the museums and flower markets at
Amsterdam. But the spell cast by the ESC academics was too
strong for me to deny. I carried home extra doses of choc-
olates for the kids and the crystals for the finance manager
back home, to make sure that I could attend the next ESC,
wherever it is.
The museums have suddenly become a non-issue.
Tiny Nair
Head, Dept of Cardiology, PRS Hospital,
Trivandrum 695012, India
E-mail address: tinynair@gmail.com
0019-4832/$ e see front matter
Copyright ª 2013, Cardiological Society of India. All rights
reserved.
http://dx.doi.org/10.1016/j.ihj.2013.10.016
